SJEPD040_D.RNA-Seq
EPN · Supratentorial EPN
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- Supratentorial EPN
- cancer_type
- EPN
- subtype
- Supratentorial EPN
- age_years
- 9.15
- fusion
- ZFTA_RELA
- e1_e2
- E1
- umap1_2d
- -3.126931056
- umap2_2d
- 0.400197735
- umap1_3d
- 0.987177268
- umap2_3d
- 2.701843439
- umap3_3d
- -1.863126535
- dataset
- EPN-StJude
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.660
- PANCREAS_BETA_CELLS+0.450
- INTERFERON_GAMMA_RESPONSE+0.440
- KRAS_SIGNALING_DN+0.420
- ALLOGRAFT_REJECTION+0.340
- APICAL_SURFACE+0.300
- UV_RESPONSE_UP+0.260
- INFLAMMATORY_RESPONSE+0.240
- IL6_JAK_STAT3_SIGNALING+0.210
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.210
Top 10 suppressed
- PROTEIN_SECRETION-0.480
- TGF_BETA_SIGNALING-0.470
- UV_RESPONSE_DN-0.450
- ANDROGEN_RESPONSE-0.440
- MITOTIC_SPINDLE-0.410
- MYC_TARGETS_V1-0.410
- UNFOLDED_PROTEIN_RESPONSE-0.340
- E2F_TARGETS-0.320
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.270
- G2M_CHECKPOINT-0.270
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-WT-AB41-01A-11R-A41B-07 | — | B | 0.877 |
| 2 | SJEPD006_D.RNA-Seq | EPN | Supratentorial EPN | 0.870 |
| 3 | TCGA-LL-A5YN-01A-11R-A28M-07 | — | B | 0.854 |
| 4 | TCGA-4Z-AA7Q-01A-11R-A39I-07 | — | — | 0.851 |
| 5 | SRR25617853 | — | D | 0.846 |
| 6 | SJEPD017_D.RNA-Seq | EPN | Supratentorial EPN | 0.842 |
| 7 | MNG718 | — | — | 0.837 |
| 8 | SJEPD001532_R1.RNA-Seq | EPN | Supratentorial EPN | 0.835 |
| 9 | TCGA-GD-A76B-01A-11R-A32O-07 | — | — | 0.832 |
| 10 | TCGA-E7-A519-01A-11R-A26T-07 | — | — | 0.828 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.660 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.450 | Cobimetinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.440 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.420 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.340 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.300 | Temsirolimus | — uncovered |
| UV_RESPONSE_UP | 0.260 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.240 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.210 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.210 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.150 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.120 | Inavolisib | — uncovered |
| MYOGENESIS | 0.110 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.100 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.070 | Inavolisib | — uncovered |
| COMPLEMENT | 0.050 | Inavolisib | — uncovered |
| COAGULATION | 0.030 | Binimetinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.030 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.020 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.010 | Inavolisib | — uncovered |